ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open Study Assessing the Safety and Tolerability of U3-1784

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02690350
Recruitment Status : Terminated (Program discontinued for business reasons (not safety).)
First Posted : February 24, 2016
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:

The main objectives of the trial are:

  • To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours
  • To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Hepatocellular Cancer (HCC) Drug: U3-1784 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Single arm, three cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours
Actual Study Start Date : February 29, 2016
Actual Primary Completion Date : February 28, 2017
Actual Study Completion Date : February 28, 2017

Arm Intervention/treatment
Experimental: Cohort 1 U3-1784 2.5 mg/kg
U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
Drug: U3-1784
Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Other Name: Experimental product

Experimental: Cohort 2 U3-1784 3.75 mg/kg
U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
Drug: U3-1784
Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Other Name: Experimental product

Experimental: Cohort 3 U3-1784 5.6 mg/kg
U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
Drug: U3-1784
Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Other Name: Experimental product




Primary Outcome Measures :
  1. Number of Patients with Adverse Events [ Time Frame: within 1 year ]
    Treatment emergent adverse events (TEAEs) are systematically collected - clinically significant changes in laboratory values are recorded as TEAEs in system organ class: Investigations

  2. Number of Patients with Dose-Limiting Toxicities (DLTs) [ Time Frame: from start of treatment until trial termination (within 2 months) ]

Secondary Outcome Measures :
  1. Maximum Concentration (Cmax) [ Time Frame: within 2 months ]
  2. Time to Cmax (Tmax) [ Time Frame: within 2 months ]
  3. Area Under the Curve to the Last Quantifiable Measure (AUClast)[ [ Time Frame: within 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Part 1: Patients with histologically or cytologically confirmed advanced solid tumours refractory to, intolerant of, or not eligible for standard treatment, or who decline standard therapy, or for whom no therapy with curative intent is available
  • Part 2: Patients with histologically or cytologically confirmed HCC refractory to, intolerant of, or not eligible for standard treatment, or who decline standard therapy, or for whom no therapy with curative intent is available. If emerging Part 1 data suggest that a particular tumour type or specific tumour histology might be responsive to treatment, then patients with this tumour type or histology will also be included in Part 2 of the study.
  • Male or female patients, 18 years of age or older.
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment.
  • Males and females of childbearing potential are permitted in the study so long as they consent to avoid getting their partner pregnant or becoming pregnant, respectively, by using a highly effective contraception method, as described below, throughout the study and for up to 90 days after completion. Highly effective methods of contraception include: hormonal methods associated with inhibition of ovulation, intrauterine device; surgical sterilization (including partner's vasectomy) or sexual abstinence, if this is the preferred and usual lifestyle of the subject. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year Eastern Cooperative Oncology Group performance status ≤ 1.
  • Life expectancy of greater than 3 months.
  • Ability to understand and the willingness to sign a written informed consent form.
  • Measurable or evaluable disease as defined by RECIST Version 1.1 in Part 1 of the study (patients included in Part 2 will be required to have measurable disease). The measurable lesion in HCC patients should not be one that has been previously treated by loco-regional therapies (e.g. TACE, RFA) unless this lesion has progressed and there is evidence of new, measurable, enhancement on dynamic imaging.
  • Patient has 1 of the following available for pharmacodynamic analyses:
  • Archived diagnostic or freshly obtained formalin-fixed paraffin embedded or frozen tumour tissue
  • Tumour tissue biopsy collected prior to study drug administration
  • Patient has adequate bone marrow, renal, and hepatic function as follows:
  • Haemoglobin: ≥ 90 g/L
  • Absolute Neutrophil Count: ≥ 1.5 × 109/L
  • Platelets: ≥ 100 × 109/L (Part 1); ≥ 75 × 109/L (Part 2)
  • Total Bilirubin: ≤ 1.5 × upper limit of normal (ULN)
  • AST (SGOT)/ALT (SGPT): ≤ 2.5 × institutional ULN
  • Prothrombin Time (PT)/International Normalised Ratio (INR): ≤ 1.5 (patients on anticoagulants will have PT and INR as determined by the Investigator)
  • Serum creatinine: ≤ 1.5 × ULN or Creatinine Clearance (calculated from serum creatinine using Cockcroft-Gault formula) ≥ 60 mL/min for patients with creatinine levels above institutional normal

Exclusion Criteria:

  • Patient has received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy or loco-regional therapy within a period of 21 days prior to Study Day 1 (6 weeks for nitrosureas or mitomycin C). Prior and concurrent use of hormone replacement therapy, use of gonadotropin-releasing hormone modulators for prostate cancer, and use of somatostatin analogues for neuroendocrine tumours are permitted.
  • Patient has unresolved clinically significant toxicities from prior anticancer therapy, defined as any National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03; Grade 2 or higher, apart from alopecia.
  • Patients with heart failure (New York Heart Association > Class II) within 6 months prior to study entry; symptomatic coronary artery disease; clinically significant cardiac arrhythmia defined as ≥ Grade 3 to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03; uncontrolled hypertension, myocardial infarction occurring within 6 months prior to study entry.
  • Patient has active clinically serious infection defined as ≥ Grade 3 to NCI CTCAE, Version 4.03.
  • Patients with clinically significant pericardial effusions, pleural effusions or ascites.
  • Patient has had another active malignancy within the past 3 years except for nonmelanoma carcinoma of the skin, cervical carcinoma in situ, and superficial bladder tumours.
  • Patient has had major surgery within 4 weeks before enrolment.
  • Patient has known hypersensitivity to colestyramine (or any of its excipients) or history of hypersensitivity/allergic reactions attributed to other monoclonal antibodies
  • Patients with complete biliary obstruction
  • Lactating women

Additional exclusion criteria for HCC patients included in Part 1 and Part 2:

  • Concomitant interferon therapy or therapies for active Hepatitis C Virus infection.
  • Patient has history of liver transplant.
  • Patient has Child-Pugh B-C cirrhotic status based on clinical findings and laboratory results during screening period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02690350


Locations
United Kingdom
Glasgow, Lanarkshire, United Kingdom, G12 0YN
The Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Guy's Hospital
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Investigators
Study Director: Alberto Martinez, PhD Daiichi Sankyo UK Ltd.

Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT02690350     History of Changes
Other Study ID Numbers: U31784-A-E101
2015-002670-20 ( EudraCT Number )
First Posted: February 24, 2016    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Liver Neoplasms
Carcinoma, Hepatocellular
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Cholestyramine Resin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents